Evidence map›Paper›PMID 19085111›Full record

ArticleThe AAPS journal2008

Method to screen substrates of apical sodium-dependent bile acid transporter.

Rana Rais, Pablo M Gonzalez, Xiaowan Zheng, Stephen A Wring, James E Polli

Abstract read
In one paragraph

Article in The AAPS journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2012
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2010
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rana RaisSchool of Pharmacy, University of Maryland, 20 Penn Street, Baltimore, Maryland 21201, USA.
Pablo M Gonzalez
Xiaowan Zheng
Stephen A Wring
James E Polli

Funding

University of Maryland Center of Excellence in Regulatory Science and InnovationU01FD005946 · FDA · UNIV OF MARYLAND, COLLEGE PARK · PI BENTLEY, WILLIAM E., POLLI, JAMES E · 2016 to 2025
$21.5M
Substrate requirements of the bile acid transporterR01DK067530 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI POLLI, JAMES E · 2005 to 2009
$1.4M
FDA HHS U01 FD005946NIDDK NIH HHS DK67530NIDDK NIH HHS R01 DK067530
6 · The paper itself

Abstract

Human apical sodium-dependent bile acid transporter (hASBT) is a potential prodrug target under study. Development of prodrugs that target hASBT may yield compounds with low solubility and/or susceptibility to hydrolysis. A transport uptake method is needed that increases compound solubility and avoids NaOH for cell lysis during postexperimental cell sample preparation. The overall goal was to develop an assay method to screen for hASBT uptake of novel compounds. The first objective was to determine the maximum cosolvent concentrations that are compatible with an hASBT active transport assay. The second objective was to develop a NaOH-free cell lysis method to process cell samples from these uptake studies. The following cosolvents were studied: dimethylacetamide (DMAC), dimethylformamide (DMF), dimethylsulfoxide (DMSO), ethanol, methanol, polyethylene glycol-400, propylene glycol, and dioxane. Initial studies included taurocholate flux studies across hASBT-Madin-Darby canine kidney monolayers using up to 10% cosolvent, as well as cytotoxicity studies. The effect of selected cosolvent concentrations on the hASBT Michaelis-Menten kinetic parameters was evaluated. Additionally, two acetonitrile-based cell lysis methods that do not use NaOH were evaluated in terms of percent sample recovery and hASBT kinetic parameters. Results showed that the maximum permissible cosolvent concentrations for hASBT uptake studies, without compromising assay results or causing cytotoxicity, are 1% DMAC, 1% DMF, 2.5% DMSO, 2.5% methanol, and 2.5% ethanol. Additionally, both NaOH-free, acetonitrile-based cell lysis methods provided similar recovery and hASBT results, compared to NaOH method. Hence, an assay method was developed to screen for active transport, allowing for cosolvents that can solubilize compounds and avoid NaOH sample treatment, which can otherwise degrade compound.

Indexed as

AcetamidesAcetonitrilesAnimalsBiological TransportBiological Transport, ActiveCarrier ProteinsCell LineDimethylformamideDimethyl SulfoxideDogsDrug Evaluation, PreclinicalHumansKidneyKineticsMembrane GlycoproteinsPolyethylene GlycolsAcetamidesacetonitrileAcetonitrilesbile acid binding proteinsCarrier ProteinsdimethylacetamideDimethylformamideDimethyl SulfoxideMembrane GlycoproteinsPolyethylene GlycolsSodium Hydroxide

Identifiers

PMID19085111
PMCPMC2628203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.